close
Add to watchlist
Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes, known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutics for up to 13 targets; and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. The company was founded in 1998 and is based in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 12.04 |
| Volume | (mio) 1.35 |
| Volume Avg | 759452 |
| 52 Week High | 11.95 |
| 52 Week Low | 5.54 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.19 |
| EPS change Q/Q | -41.18% |
| EPS change Q/Q Yr ago | -23.08% |
| EPS change Q/Q next Q est | -23.08% |
| EPS change Y/Y | -20.75% |
| REV change Q/Q | 108.33% |
| REV change Q/Q Yr ago | 120.59% |
| EPS next Q est | -0.13 |
| EPS next Y est | -0.26 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |